Signed a definitive agreement under which Merck will acquire Afferent Pharmaceuticals . Under terms, Merck, through unit, to acquire outstanding stock of Afferent for an upfront payment of $500 million in cash .Afferent shareholders will be …
LONDON Roche's immunotherapy drug Tecentriq has lost market share to Merck & Co's rival Keytruda since a clinical trial showed the Swiss company's medicine failed to improve overall survival in bladder cancer. LONDON, Oct 5 Roche's …
Drug stocks are soaring Wednesday, after Democratic presidential candidate Hillary Clinton, who had outlined plans to to curb drug price increases was defeated by Republican Donald Trump. Biotech investors had been skittish about what a …
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal …
KKR is doing well despite the tougher climate, surely giving it an advantage going ahead. Merck & Co. Inc. (NYSE:MRK), a component of the S&P 500, beat its figures from 2011 posting earnings of 56 cents per share compared with Q1 2011’s …
The chief executives of Merck and Under Armour chief resigned Monday from a White House advisory panel on manufacturing after President Donald Trump's initial failure to explicitly condemn a white supremacist rally. "America's …